<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>72</patient-age><report-id>KR-ELI_LILLY_AND_COMPANY-KR201212005061</report-id><gender>female</gender><reactions><reaction>Breath shortness</reaction><reaction>Abdominal discomfort</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>HUMALOG LISPRO</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Type 2 diabetes mellitus</indication></indications><patient-age>72</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Korea, Republic of</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>734880_111</messagenumb>
		<messagesenderidentifier>LILLYFDA</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151006</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>KR-ELI_LILLY_AND_COMPANY-KR201212005061</safetyreportid>
		<primarysourcecountry>KR</primarysourcecountry>
		<occurcountry>KR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-16</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-17</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-14</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>KR-ELI_LILLY_AND_COMPANY-KR201212005061</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reportercountry>KR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reportercountry>KR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>Eli Lilly and Company</senderorganization>
			<senderdepartment>BS200</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>John</sendergivename>
			<sendermiddlename>A.</sendermiddlename>
			<senderfamilyname>Fredenburg</senderfamilyname>
			<senderstreetaddress>Lilly Corporate Center</senderstreetaddress>
			<sendercity>Indianapolis</sendercity>
			<senderstate>IN</senderstate>
			<senderpostcode>46285</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2770207</sendertel>
			<sendertelcountrycode>317</sendertelcountrycode>
			<senderfax>8666441697</senderfax>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>Food and Drug Administration - CDER</receiverorganization>
			<receiverdepartment>Office of Surveillance and Epidemiology</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20851</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3017709299</receivertel>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3017706614</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JGL</patientinitial>
			<patientonsetage>72</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Type 2 diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Breath shortness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Breath shortness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspnoea</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201212</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Abdominal discomfort</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Abdominal discomfort</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal discomfort</reactionmeddrapt>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201212</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>X-ray</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>HUMALOG LISPRO</medicinalproduct>
				<obtaindrugcountry>KR</obtaindrugcountry>
				<drugauthorizationnumb>20-563</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Eli Lilly and Company</drugauthorizationholder>
				<drugstructuredosagenumb>6</drugstructuredosagenumb>
				<drugstructuredosageunit code="025"/>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>6 u, bid</drugdosagetext>
				<drugdosageform normalized="injection">Injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Type 2 diabetes mellitus</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-28</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>INSULIN, LISPRO</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal discomfort</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal discomfort</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>NHCP</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This spontaneous case, reported by a consumer via a patient support program <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse</Semaphore>, who <Semaphore x="1802982" class="Disease or Finding" value="Communication Disorder" score="1.00" ID="C2958">contacted </Semaphore>the company to report an <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">adverse event</Semaphore>, <Semaphore x="1805433" class="Procedure" value="Concern About Finances" score="1.00" ID="C104604">concerns </Semaphore>a 72 years old <Semaphore x="1548893" class="Race" value="Asian American" score="1.00" ID="C16310">Asian </Semaphore>female patient. Additional information received from the consumer via a patient support program <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse</Semaphore>.Medical history: <Semaphore x="2659498" class="Disease or Finding" value="Type 2 Diabetes Mellitus" score="1.00" ID="C26747">type 2 diabetes mellitus</Semaphore>. Concomitant medications were not provided.The patient received <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.74" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">insulin </Semaphore>lispro </Semaphore>(<Semaphore x="669768" class="Medicine" value="Humalog" score="0.49" ID="228096">Humalog</Semaphore>; KwikPen) 6 units/ 10 units bid subcutaneously for <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="2659498" class="Disease or Finding" value="Type 2 Diabetes Mellitus" score="1.00" ID="C26747">type II diabetes mellitus </Semaphore>on 28Nov2012. Around 12Dec2012 or 13Dec2012, reported as four to five days prior to report of 17Dec2012, the patient experienced <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968"><Semaphore x="1647857" class="AnatomicStructure" value="Breath" score="1.00" ID="C94552">breath </Semaphore>shortness </Semaphore>and <Semaphore x="2705992" class="MedDRA LLT" value="Abdominal discomfort" score="1.00" ID="10000059">abdominal <Semaphore x="1854131" class="Disease or Finding" value="Discomfort" score="1.00" ID="C50535">discomfort </Semaphore></Semaphore>that were continued. On 14Dec2012 the patient was hospitalized for the events. The patient received an <Semaphore x="2443785" class="Procedure" value="Radiography" score="1.00" ID="C38101">x ray </Semaphore><Semaphore x="2444079" class="Procedure" value="Radionuclide Imaging" score="1.00" ID="C62667">scan </Semaphore>in the hospital, <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>were pending. No other laboratory <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results</Semaphore>, <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>measures were provided. On an unknown date in late Dec 2012, the patient was transferred to another hospital with an unknown admitting <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>because there was no more treatment the hospital <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">doctor </Semaphore>could do. On 08-Jan 2013, the patient was discharged from the second <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>. No additional information regarding the <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>was provided. At the time of report, <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="627832" class="Medicine" value="Glucose" score="0.49" ID="269493">glucose </Semaphore><Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.58" ID="C91103">was well </Semaphore><Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled </Semaphore>and the <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events was recovered. <Semaphore x="730644" class="Medicine" value="Insulin Lispro" score="0.74" ID="290552"><Semaphore x="2809836" class="MedDRA LLT" value="Blood insulin" score="1.00" ID="10005605">Insulin </Semaphore>lispro </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was continued.Update15-Jan 2013: Additional information was received from the consumer via patient support program on 14-Jan 2013. Updated <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of events to recovered. Updated narrative. No other changes were <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">made</Semaphore>.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>